XYLEXA

SaMD and CADx: Effectiveness in Medical Diagnosis

Introduction

The healthcare industry has witnessed a significant transformation in recent years, with the advent of technology. One of the most promising technologies is the use of Software as a Medical Device (SaMD) for medical diagnosis, including the computer-aided diagnosis (CADx). This white paper explores the effectiveness of SaMD for diagnosis via CADx, focusing on its use in breast cancer diagnosis.

SaMD has revolutionized the healthcare industry by offering innovative solutions for medical diagnosis and treatment. The FDA defines SaMD as "software intended for use in the diagnosis, treatment, mitigation, or prevention of disease or other conditions." [1] The EU MDR refers to SaMD as "software that is a medical device in its own right and not a part of a hardware medical device." [2] The IMDRF defines SaMD as "software intended to be used for one or more medical purposes that perform these purposes without being part of a hardware medical device." [3]

SaMD devices offer a wide range of medical applications, including diagnosis, monitoring, and treatment. Examples of SaMD devices include computer-assisted diagnosis (CADx) for breast cancer diagnosis, electrocardiogram (ECG) interpretation software, mobile health applications, and clinical decision support systems. SaMD devices can analyze vast amounts of patient data and provide more accurate and reliable diagnoses. Moreover, they can offer innovative treatment options that can be accessed remotely, making it easier for healthcare providers to diagnose and treat patients.

As the use of SaMD becomes more widespread, regulatory frameworks for SaMD have been established by the FDA, the EU MDR, and the IMDRF to ensure that SaMD is safe and effective for medical purposes. These frameworks help to address the limitations and challenges associated with SaMD devices, such as data quality, liability issues, and regulatory compliance.

In 2020, female breast cancer became the most common type of cancer with an estimated 2.3 million new cases (11.7%), followed by lung cancer (11.4%). Treatment of BC relies on conducting an accurate diagnosis, including histological, molecular, and clinical phenotypes. Non-invasive imaging techniques such as mammography, ultrasound, and magnetic resonance (MR) are available for qualitative and quantitative analysis of BC in clinical practice. The American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) is a standardized assessment structure that enables radiologists to clearly and concisely communicate results of breast imaging to referring physicians. In the fifth edition of the BI-RADS atlas, category 4 and 5 breast lesions are defined as suspicious cancerous lesions, and a biopsy is recommended for further diagnosis.

Recent studies have shown that a large number of benign lesions are present in category 4 and 5 breast lesions, particularly in the mammography reporting system, exposing these patients to invasive biopsies. Depending on the technique, the sensitivity values of biopsy results ranged from 87% to >97%. **[4-9]**



FIGURE 1 Color-coded Bounding Boxes Exhibits by XyCAD-MMG on Left and Right Craniocaudal (CC) and mediolateral oblique position (MLO) images of Mammography

Benefits of SaMD for Diagnosis

The use of SaMD for diagnosis via CADx has many potential benefits. Firstly, it can improve the accuracy of diagnoses. SaMD can analyze vast amounts of patient data, detect patterns and outliers, and provide more accurate and reliable diagnoses. In the context of breast cancer diagnosis, CADx can help reduce the rate of false positives and false negatives in mammography, thereby avoiding unnecessary treatments or missed diagnoses.

Another benefit of SaMD for diagnosis via CADx is increased access to healthcare. This technology can bring diagnostic tools to underserved areas, allowing doctors and other healthcare professionals to diagnose and treat patients remotely. This is particularly beneficial in rural areas where there may be a shortage of healthcare providers. Additionally, the use of SaMD for diagnosis via CADx can lead to lower costs, making it more accessible to patients and healthcare providers.

SaMD for breast cancer diagnosis via CADx can lead to a reduction in patient anxiety. Mammography is a sensitive test, and women may be anxious about the results of the test. CADx can reduce the number of false positives, thus decreasing the number of unnecessary biopsies and reducing patient anxiety.

Limitations of SaMD for Diagnosis

While SaMD for diagnosis via CADx has many benefits, there are also several limitations. One of the major limitations is the lack of adequate data quality. The

performance of SaMD is dependent on the quality and accuracy of data used to develop it. Therefore, the accuracy and reliability of SaMD are only as good as the quality of data that is fed into it. Additionally, SaMD may suffer from limitations due to the fact that the data on which it is trained may not be representative of the entire population.

Another limitation of SaMD is the potential for liability issues. The use of SaMD for diagnosis via CADx requires that the system performs at a high level of accuracy. Therefore, when SaMD is used to diagnose a patient, it becomes a part of the patient's medical record, and any error or mistake can lead to significant harm to the patient. Therefore, there is a need to establish legal and regulatory frameworks to deal with liability issues arising from the use of SaMD.

Conclusion

SaMD for diagnosis via CADx has the potential to provide significant benefits to patients and healthcare providers, particularly in the context of breast cancer diagnosis. Improved accuracy, time savings, increased access to healthcare, and lower costs are just a few of the potential benefits of this technology. However, it is important to consider the limitations of SaMD and work to address issues around data quality, liability, and regulatory compliance. With continued development and refinement, SaMD for diagnosis via CADx could transform medical diagnosis and improve patient outcomes. The regulatory frameworks established by the FDA, EU, and IMDRF provide a framework for SaMD development and regulation, but it is important to ensure that this technology is used in conjunction with the skills and expertise of healthcare providers. By doing so, we can harness the power of technology to provide better healthcare to patients.

References:

1. U.S. Food and Drug Administration. (2021). Software as a Medical Device (SaMD). Retrieved from https://www.fda.gov/medical-devices/digital-health/software-medical-device-samd
2. European Commission. (2017). Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Retrieved from https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0745&from=EN
3. International Medical Device Regulators Forum. (2013). Software as a Medical Device (SaMD): Key Definitions. Retrieved from https://www.imdrf.org/documents/documents/imdrf/final/imdrf-final-samd-key-definitions-130910.pdf
4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* (2021) 71:209–49. doi: 10.3322/caac.21660

5. Strobel K, Schrading S, Hansen NL, Barabasch A, Kuhl CK. Assessment of BI-RADS Category 4 Lesions Detected With Screening Mammography and Screening US: Utility of MR Imaging. Radiology (2015) 274:343–51. doi: 10.1148/radiol.14140645
6. Bickelhaupt S, Jaeger PF, Laun FB, Lederer W, Daniel H, Kuder TA, et al. Radiomics Based on Adapted Diffusion Kurtosis Imaging Helps to Clarify Most Mammographic Findings Suspicious for Cancer. Radiology (2018) 287:761–70. doi: 10.1148/radiol.2017170273
7. Alì M, D'Amico NC, Interlenghi M, Maniglio M, Fazzini D, Schiaffino S, et al. A Decision Support System Based on BI-RADS and Radiomic Classifiers to Reduce False Positive Breast Calcifications at Digital Breast Tomosynthesis: A Preliminary Study. Appl Sci (2021) 11:2503. doi: 10.3390/app11062503
8. Wang M, He X, Chang Y, Sun G, Thabane L. A Sensitivity and Specificity Comparison of Fine Needle Aspiration Cytology and Core Needle Biopsy in Evaluation of Suspicious Breast Lesions: A Systematic Review and Meta-Analysis. Breast (2017) 31:157–66. doi: 10.1016/j.breast.2016.11.009
9. Youk JH, Kim EK, Kim MJ, Lee JY, Oh KK. Missed Breast Cancers at US-Guided Core Needle Biopsy: How to Reduce Them. Radiographics (2007) 27:79–94. doi: 10.1148/rg.271065029